Nuclear Medicine & Radiation Therapy

Yasser Bayoumi

Publications

• Research Article
  Bladder Preservation with Concurrent Radiotherapy and Gemcitabine following Maximal Transurethral Resection for Muscle Invasive Bladder Cancer: Single Institutional Experience
  
  Author(s): Mutahir A. Tunio, Mushabbab Al Asiri, Mohsin Fareed, Shoaib Ahmed, Yasser Bayoumi and Abdullah AmroMutahir A. Tunio, Mushabbab Al Asiri, Mohsin Fareed, Shoaib Ahmed, Yasser Bayoumi and Abdullah Amro
  
  Abstract Objectives: For bladder preservation, cisplatinum is widely used radiosensitizer with concurrent chemoradiation (CRT). We aimed to evaluate the safety profile and potential benefit of gemcitabine as a radiosenistizer in bladder preservation. Patients and methods: During July 2006 to January 2007, consecutive 32 patients with T2-T4N0M0 bladder cancer underwent transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiation with weekly gemcitabine 100 mg/m2 . Conformal radiotherapy was given with a shrinking field technique. Complete response was defined as no visible tumor on cystoscopy and biopsy. Results: Of total, 26 patients received a median of 7 (3–8) cycles of gemcitabine and median cumulative radiation dose of 65 Gy. Grade 3 hematologic toxicities seen were; neutropenia (3.8%) and thrombocytopenia (7.7%). Grade 3 non-hem.. Read More»
  DOI: 10.4172/2155-9619.1000121

  Abstract